From: One-and-a-half nostril endoscopic transsphenoidal approach for pituitary adenomas—a technical report
Patient age, mean ± SD, y | 49.7 ± 14.1 |
Male/female, n | 35/22 |
Follow up (range), mo | 18 (6–24) |
Tumor with volumes mm3 | 22*20*20 |
Recurrent, n (%) | 7 (12.3%) |
Presenting symptoms, n (%) | |
Abnormal visual functions | 32 (56%) |
Endocrinopathy | 18 (32%) |
Headache | 13 (23%) |
Incidental | 7 (12%) |
Pituitary apoplexy | 6 (11%) |
Knosp score, n (%) | |
0 | 3 (5.3%) |
1 | 8 (14.0%) |
2 | 16 (28.1%) |
3 | 19 (33.3%) |
4 | 11 (19.3%) |
Nonfunctioning adenoma, n (%) | 39 (68.4%) |
Functioning adenoma, n (%) | 18 (31.6%) |
Growth hormone | 12 (21.1%) |
Prolactinomas | 4 (7.0%) |
ACTH | 2 (3.5%) |